NCT01640314View on ClinicalTrials.gov

Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

PHASE3CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Influenza
Interventions
BIOLOGICAL

Cell derived subunit trivalent nonadjuvanted vaccine

A single 0.5 mL dose of the cell derived subunit trivalent nonadjuvated influenza vaccine (TIVc) supplied in prefilled syringes and administered intramuscularly in the deltoid muscle (preferably) of the non dominant arm.

Trial Locations (1)

D-20359

Bernhard Nocht Institute, Bernhard-Nocht-Strasse 74

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY